Literature DB >> 18466028

The utility of p16(Ink4a) in discriminating between cervical intraepithelial neoplasia 1 and nonneoplastic equivocal lesions of the cervix.

Rachel Redman1, Irina Rufforny, Chen Liu, Edward J Wilkinson, Nicole A Massoll.   

Abstract

CONTEXT: The protein p16(Ink4a) is overexpressed in cervical lesions associated with high-risk human papillomavirus (HPV) subtypes 16 and 18, but not in low-risk HPV subtypes 6 and 11 or non-HPV-associated cervical lesions.
OBJECTIVE: To determine whether p16(Ink4a) expression in equivocal cervical lesions helps distinguish atypical non-HPV changes from HPV-related changes.
DESIGN: One hundred ninety-one cervical lesions, including 81 cervical intraepithelial neoplasia 1, 52 squamous metaplasia, 33 cellular features suggestive of HPV-related change, 9 reserve cell hyperplasia, 4 microglandular hyperplasia, and 12 inflammatory cervicitis, were randomly selected from archival cervical biopsy specimens. All 191 samples were studied with p16(Ink4a) (JC8 monoclonal antibody). Reactivity for p16(Ink4a) was scored on a 3-tier system as follows: negative, 0% to 5% cells reactive; focal/scattered positive, greater than 5% and less than or equal to 80% cells reactive; diffuse positive, greater than 80% cells reactive. Reactivity was based on normal/reactive cervical specimens where anti-p16 antibody was negative/weakly expressed in non-cervical epithelial cells. Cervical intraepithelial neoplasia 1 lesions not reactive for p16(Ink4a) were investigated for the presence of high-risk HPV by real-time polymerase chain reaction.
RESULTS: No p16(Ink4a) reactivity was detected in the cervical lesions associated with atypical non-HPV change. Eleven of the cervical intraepithelial neoplasia 1 lesions showed focal/scattered reactivity expression for p16(Ink4a), and 19 of the CIN 1 lesions had diffuse reactivity. Fifty of 51 of the CIN 1 lesions negative for p16(Ink4a) were real-time polymerase chain reaction negative for the presence of high-risk HPV; 1 was real-time polymerase chain reaction positive for high-risk HPV.
CONCLUSIONS: The data support the routine use of p16(Ink4a) immunohistochemical evaluation of cervical biopsy specimens for better discrimination of non-HPV-associated lesions from HPV-related lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466028     DOI: 10.5858/2008-132-795-TUOPID

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker.

Authors:  Luisa F Escobar-Hoyos; Jie Yang; Jiawen Zhu; Julie-Ann Cavallo; Haiyan Zhai; Stephanie Burke; Antonius Koller; Emily I Chen; Kenneth R Shroyer
Journal:  Mod Pathol       Date:  2013-09-20       Impact factor: 7.842

2.  p16 Immunohistochemistry Interpretation by Nonpathologists as an Accurate Method for Diagnosing Cervical Precancer and Cancer.

Authors:  Guang-Dong Liao; Le-Ni Kang; Wen Chen; Xun Zhang; Xiao-Yang Liu; Fang-Hui Zhao; Mark H Stoler; Anne Mills; Ming-Rong Xi; You-Lin Qiao; Philip E Castle
Journal:  J Low Genit Tract Dis       Date:  2015-07       Impact factor: 1.925

3.  Expression of P63, P16 and CK17 in Atypical Squamous Metaplasia and Cervical Intraepithelial Neoplasia.

Authors:  Maryam Iranpour; Shahriar Dabiri; Mitra Rezazade-Jabalbarezi; Fatemeh Bagheri
Journal:  Iran J Pathol       Date:  2020-12-26

4.  Human papillomavirus E6E7 mRNA and TERC lncRNA in situ detection in cervical scraped cells and cervical disease progression assessment.

Authors:  Hui Zhao; Yue He; Bei Fan; Yan Wang; Yu-Mei Wu
Journal:  Virol J       Date:  2022-01-24       Impact factor: 4.099

5.  Expression of pRb and p16INK4 in human thymic epithelial tumors in relation to the presence of human polyomavirus 7.

Authors:  Marlies Keijzers; Dorit Rensspiess; Sreedhar Pujari; Myrurgia A Abdul-Hamid; Monique Hochstenbag; Anne-Marie Dingemans; Anna Kordelia Kurz; Anke Haugg; Jos G Maessen; Marc H De Baets; Axel Zur Hausen
Journal:  Diagn Pathol       Date:  2015-11-04       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.